The product functions as an intelligent layer within the broader Veeva AI suite, focusing on the labor-intensive aspects of pharmacovigilance. By automating the follow-up and intake stages, the company intends to lower operational costs while accelerating response times for biopharma organizations. Marius Mortensen, vice president of product for Falcon, noted that the tool was developed through direct collaboration with global safety specialists and case processors to modernize legacy operations.

Early adopter availability is scheduled for November 2026. This release marks a shift toward agnostic interoperability, allowing companies to integrate Falcon Safety into existing infrastructure without replacing their current safety databases. Veeva currently serves over 1,500 customers, positioning this AI-native tool as a scalable solution for both emerging biotech firms and large-scale pharmaceutical enterprises.